Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
Cellular Intelligence acquires Novo Nordisk's Parkinson's disease cell therapy company
Investing.com – The biotech company Cellular Intelligence, supported by Meta CEO Mark Zuckerberg, announced on Monday that it has acquired a cell therapy candidate for treating Parkinson’s disease from Danish pharmaceutical company Novo Nordisk.
Novo Nordisk shut down its cell therapy division last October during a broader business restructuring and subsequently ceased development of the therapy.
The specific financial terms of the deal were not disclosed. According to the biotech company, Novo Nordisk will receive equity in Cellular Intelligence and may receive milestone payments and royalties in the future.
The therapy is called STEM-PD, an allogeneic stem cell-derived treatment designed to replace dopamine-producing neurons lost in Parkinson’s patients. Parkinson’s disease is a progressive brain disorder that can cause tremors, muscle rigidity, and slowed movement.
Cellular Intelligence stated that it plans to leverage its proprietary AI platform to accelerate the therapy’s development, scale up production, and reduce costs, while also using the data obtained to further train AI models.
Novo Nordisk
Focus
Analysis NVO
Included in our AI-selected strategies
·
View strategy details
46.07
▲+0.27(+0.59%)
Close·09/05·USD
47.04
▲+0.97(+2.11%)
Pre-market·12:52:59
1 day
1 week
1 month
6 months
1 year
5 years
Max
Created with Highcharts 11.4.814:0015:0016:0017:0018:0019:004545.2545.545.7546
Analysis NVO
Cellular Intelligence CEO Micha Breakstone said, “This marks the beginning of the era where cell replacement therapies enter the AI-native age — an era where biology is no longer fate, but a design.”
The therapy is currently in early to mid-stage clinical trials and has received Fast Track designation from the U.S. Food and Drug Administration (FDA), aimed at expediting review processes for therapies targeting serious diseases with unmet medical needs.
Cellular Intelligence has raised over $60 million from investors including Khosla Ventures and the Chan Zuckerberg Initiative, founded by Zuckerberg.
This article was translated with AI assistance. For more information, see our Terms of Use.